Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...
'Inheritance through homology' is the most common and generally more accessible approach to function prediction, but orthology should be established where possible to improve confidence in predictions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback